B. Riley Securities Maintains Neutral on Mirati Therapeutics, Lowers Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Kalpit Patel has maintained a Neutral rating on Mirati Therapeutics (NASDAQ:MRTX) and lowered the price target from $51 to $45.
July 24, 2023 | 3:23 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
B. Riley Securities has maintained a Neutral rating on Mirati Therapeutics and lowered the price target from $51 to $45.
The lowering of the price target by B. Riley Securities could potentially lead to a decrease in the stock price of Mirati Therapeutics in the short term. This is because the new price target is lower than the previous one, indicating a less optimistic outlook for the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100